March S&P 500 E-Mini futures (ESH26) are down -0.44%, and March Nasdaq 100 E-Mini futures (NQH26) are down -0.66% this ...

SAN FRANCISCO — Despite all the hopeful chatter about the life sciences industry making a rebound after a multiyear ...

Moderna shares surge 30% in 2026 on raised revenue forecast and cost cuts. Technical breakout suggests continued momentum ...

At the 44 th Annual JP Morgan Healthcare Conference on Monday, Moderna Inc. (NASDAQ:MRNA) said that it expects to report ...

Major stock indexes ended lower Tuesday, a day after the S&P 500 and Dow Jones Industrial Average set fresh records, as investors digested a consumer inflation reading that matched expectations and ...

The firm is expecting a slew of key readouts for mRNA vaccines for treating cancer and rare diseases and is exploring vaccines for autoimmune conditions.

Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a ...

I agree to the Terms of Use , Privacy Notice and Cookie Notice.

In a shocking turn of events, Bayer, through its controversial Monsanto division, has filed a lawsuit against major COVID-19 vaccine producers Pfizer, BioNTech, Moderna, and Johnson & Johnson. This ...

Expects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 ...

While Moderna’s full-year sales landed in the upper end of its target range, Jefferies analysts said further reductions are ...

Moderna Inc. said its US Covid business did better than expected last year, a rare bright spot for the vaccine maker, which ...